STOCKHOLM, Sweden—Everolimus-eluting stents (EES) appear to provide improved long-term outcomes compared with sirolimus-eluting stents (SES), in part due to a lower risk of myocardial infarction (MI) associated with stent thrombosis, according to non-randomized findings presented Monday, August 30, 2010, at the European Society of Cardiology Congress. At 3 years EES reduce ischemic endpoints vs. SES. No difference in mortality. Lower stent thrombosis may be key to EES superiority.
